Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation Results of a Phase 2 trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export (SINE) in 114 Patients with Gynaecological Cancers PDF (1.37 MB) Read MorePaper Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death PDF (2.61 MB) Read MorePaper Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone PDF (2.41 MB) Read MorePaper Inhibition of the nuclear export receptor xpo1 as a therapeutic target for platinum resistant ovarian cancer PDF (6.21 MB) Read MorePaper Heterozygous mutation of cysteine 528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export PDF (3.10 MB) Read MorePaper ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization PDF (3.00 MB) Read MorePaper Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors PDF (86.77 KB) Read MorePaper Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia PDF (2.13 MB) Read MorePaper Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma External Link Read MorePaper Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth External Link Read More Previous 1 … 6 7 8 9 10 … 22 Next